About

James Brindle is a clinical researcher specializing in radiation oncology, with a particular focus on the application of stereotactic body radiosurgery (SBRT) and robotic radiosurgery technologies in the treatment of gynecologic malignancies. His work has addressed one of oncology's most persistent challenges: managing recurrent and metastatic gynecologic cancers in patients whose treatment options are severely constrained by prior surgery, chemotherapy, and radiation exposure. Brindle's most influential contribution is his 2012 phase II clinical trial evaluating robotic SBRT for metastatic gynecologic cancers, which has garnered over 100 citations and established an important evidence base for this approach in a historically difficult-to-treat population. His earlier investigations into SBRT for pelvic relapses (2009, 52 citations) and CyberKnife radiosurgery for recurrent vulvar carcinoma (2008, 33 citations) helped lay the groundwork for these more expansive trials. He has also examined the hematological toxicity profile associated with these techniques, contributing critical safety data to the field. Collectively, his body of work — spanning clinical trials, toxicity assessment, and technical reviews — has meaningfully advanced the integration of precision radiotherapy into gynecologic oncology practice, offering renewed hope to patients with otherwise limited therapeutic options.

Research Focus

Key Achievements

5
H-Index
6
Papers
218
Total Citations
36
Avg Citations/Paper
🏆 Most Cited Paper
Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies
103 citations · 2012
📈 Most Prolific Year: 2012 (4 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: University Hospitals of Cleveland, Case Western Reserve University, University School, University Hospitals Cleveland Medical Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago